# US 2024/0390432 A1 · Engineered vectors and organisms containing the same for isoflavone conversion in the gut

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0390432 A1
- Document ID: US20240390432A1
- Status: Published application
- Kind: A1
- Application number: 18/697,325
- Filed: 2022-09-30
- Published: 2024-11-28
- Earliest claimed: 2021-09-30
- Assignees: Board of Regents, The University of Texas System
- Applicants: Board of Regents, The University of Texas System
- Inventors: Justyn JAWORSKI
- Web page: https://patentgrep.com/patent/US20240390432A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- C12N 1/20: Bacteria; Culture media therefor
- C12N 9/0071: {acting on paired donors with incorporation of molecular oxygen (1.14)}
- C12N 15/70: Vectors or expression systems specially adapted for E. coli
- C12R 2001/19: Escherichia coli
- C12Y 114/14: with reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (1.14.14)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12Y: ENZYMES

## Abstract

Generally, the present disclosure contemplates engineered vectors, organisms (e.g., bacteria or bacteriophage) containing the same, and methods for treating the gut of mammalian species by providing the organism containing the engineered vector to the gut of a mammal. Example engineered organisms can include one or more genes isolated from microbial populations for promoting isoflavone metabolism.

## Claims

### Claim at position 1

1-24. (canceled)

### Claim 25

A method for modifying the phenotype of a mammalian gut comprising:
introducing to the mammalian gut a probiotic for the treatment of cardiovascular disease (CVD) comprising:
a bacterium from the genus Escherichia containing therein at least two stable plasmids for isoflavone metabolism, said plasmids providing one or more components of isoflavone metabolism for converting Daidzein to Equol, Genistein to 5-Hydroxy-Equol, or both.

### Claim 26 (depends on 25)

The method of claim 25, further comprising co-administering a transduction agent.

### Claim 27 (depends on 26)

The method of claim 26, wherein the transduction agent comprises an antibiotic, a polycation, a bacteriophage, or a combination of two or more of the foregoing.

### Claim 28 (depends on 25)

The method of claim 25, wherein introducing the probiotic to the mammalian gut is performed according to a dosage regimen.

### Claim 29 (depends on 28)

The method of claim 28, wherein the dosage regimen comprises:
introducing the probiotic having a concentration of the bacterium to the mammalian gut at a dosing schedule over the course of a time period.

### Claim 30 (depends on 29)

The method of claim 29, wherein the concentration is between 1×106 to 1×1010 CFU/mL.

### Claim 31 (depends on 29)

The method of claim 29, wherein the time period is selected from: every 4 hours, every 6 hours, every 12 hours, every 24 hours, or every 48 hours.

### Claim 32 (depends on 29)

The method of claim 29, wherein the time period is 1 day, 1 week, 1 month, or one year.

### Claim 33 (depends on 25)

The method of claim 25, wherein the probiotic comprises:
a first bacterium having a first plasmid comprising the nucleotide sequence or sequences encoding DZNR, DDRC, or both; and
a second bacterium having a second plasmid comprising the nucleotide sequence or sequences encoding DHDR, THDR, or both.

### Claim 34 (depends on 33)

The method of claim 33, wherein the ratio of the first bacterium to the second bacterium is no less than 9:1 and no greater than 1:9.

### Claim at position 12

35-37. (canceled)

### Claim 38 (depends on 33)

The method of claim 33, wherein the nucleotide sequence encoding Daidzein reductase (DZNR) comprises the sequence of SEQ ID 1.

### Claim 39 (depends on 33)

The method of claim 33, wherein the nucleotide sequence encoding Dihydrodaidzein racemase (DDRC) comprises the sequence of SEQ ID 2.

### Claim 40 (depends on 33)

The method of claim 33, wherein the nucleotide sequence encoding Dihydrodaidzein reductase (DHDR) comprises the sequence of SEQ ID 3.

### Claim 41 (depends on 33)

The method of claim 33, wherein nucleotide sequence encoding Tetrahydrodaidzein reductase (THDR) comprises the sequence of SEQ ID 4.

### Claim 42 (depends on 25)

The method of claim 25, wherein the first plasmid further comprises an antibiotic resistance gene, and wherein the second plasmid further comprises an antibiotic resistance gene.

### Claim 43 (depends on 42)

The method of claim 42, wherein the antibiotic resistance gene of the first plasmid or the antibiotic resistance gene of the second plasmid is an ampicillin or a kanamycin resistance gene.

### Claim 44 (depends on 25)

The method of claim 25, wherein the probiotic comprises a dosage form that can be taken orally.

### Claim 45 (depends on 44)

The method of claim 44, wherein the dosage form comprises a liquid, a foodstuff, or a capsule.
